Eli Lilly Immunology Division Reaches $2.6 Billion Revenue in H1 2026
Resolved · earnings · Occurred · Assessed · 1 sources
This assessment is dated 2026-09-13. Check what remains unresolved below before relying on it.
Does the new outlook change what the company is worth?
Diversification into non-incretin therapeutic franchises protects long-term revenue durability against GLP-1 concentration risk.
| Question | What the evidence establishes |
|---|---|
| What was reported? | Reported factEli Lilly's Immunology business generated $2.6 billion in revenue during the first half of 2026, representing a 9% year-over-year increase. |
| What else was confirmed? | Reported factImmunology revenue accounted for 6.1% of Eli Lilly's total net sales in H1 2026. |
| Does the valuation support acting? | Interpretation5 stored valuation assumptions for LLY; the latest is dated 2026-08-06. |
| What would change the assessment? | UnknownEli Lilly Q3 Division Sales — Evaluate quarterly sales updates for Omvoh and Ebglyss commercial trajectory. |
What would this event cost your holdings?
Apply your own hypothetical returns to current holding values. The calculator does not infer security effects from this event.
Test this event against my holdingsReported facts
- · Eli Lilly's Immunology business generated $2.6 billion in revenue during the first half of 2026, representing a 9% year-over-year increase.
- · Immunology revenue accounted for 6.1% of Eli Lilly's total net sales in H1 2026.
- · The portfolio is anchored by Taltz and expanding with newer therapies Ebglyss and Omvoh.
- · Eli Lilly has completed strategic bolt-on acquisitions of DICE Therapeutics, Morphic Holding, and Merida to expand its pipeline.
Public research record
Research framework · page evidenceCompleted event assessment
non-GLP-1 revenue base diversification and pipeline commercialization
| Type | Claim | Scope |
|---|---|---|
| Assumption | Eli Lilly's Immunology business generated $2.6 billion in revenue during the first half of 2026, representing a 9% year-over-year increase. | 2026-09-13 |
| Interpretation | non-GLP-1 revenue base diversification and pipeline commercialization | LLY |
Countercase, invalidators, and sources
Commercial uptake of Ebglyss and Omvoh accelerates, lifting immunology revenue contribution above 8% of sales.
- · Eli Lilly Q3 Division Sales — Evaluate quarterly sales updates for Omvoh and Ebglyss commercial trajectory.
- Eli Lilly's Immunology Push Builds New Growth Engines Beyond GLP-1s · 2026-09-11
What remains unresolved
- Base path
- Immunology sales maintain steady high single-digit percentage growth led by Taltz prescriptions.
- Adverse path
- Competitive biologic therapies in dermatology and gastroenterology slow new patient starts for Ebglyss.
- Supportive path
- Commercial uptake of Ebglyss and Omvoh accelerates, lifting immunology revenue contribution above 8% of sales.
- · Eli Lilly Q3 Division Sales — Evaluate quarterly sales updates for Omvoh and Ebglyss commercial trajectory.next month
Evidence
- Eli Lilly's Immunology Push Builds New Growth Engines Beyond GLP-1s2026-09-11
“Eli Lilly's Immunology division generated $2.6 billion in revenues in H1 2026, up 9% year-over-year, representing 6.1% of total revenues... Led by Taltz, the portfolio is expanding through newer products like Ebglyss and Omvoh...”
Supports: Eli Lilly immunology sales reached $2.6B in H1 2026 (+9% YoY), accounting for 6.1% of total revenues.